vs
Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and Syndax Pharmaceuticals Inc (SNDX). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $68.5M, roughly 1.1× Syndax Pharmaceuticals Inc). On growth, Syndax Pharmaceuticals Inc posted the faster year-over-year revenue change (791.7% vs 27.7%).
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
Syndax Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies for patients with hard-to-treat cancers. Its pipeline includes targeted and immunotherapy candidates addressing unmet medical needs, primarily serving global oncology healthcare stakeholders and patient populations.
PBYI vs SNDX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.5M | $68.5M |
| Net Profit | — | $-68.0M |
| Gross Margin | 69.3% | — |
| Operating Margin | 22.7% | -91.3% |
| Net Margin | — | -99.3% |
| Revenue YoY | 27.7% | 791.7% |
| Net Profit YoY | — | 27.8% |
| EPS (diluted) | $0.26 | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.5M | $68.5M | ||
| Q3 25 | $54.5M | $45.9M | ||
| Q2 25 | $52.4M | $38.0M | ||
| Q1 25 | $46.0M | $20.0M | ||
| Q4 24 | $59.1M | — | ||
| Q3 24 | $80.5M | $12.5M | ||
| Q2 24 | $47.1M | — | ||
| Q1 24 | $43.8M | $0 |
| Q4 25 | — | $-68.0M | ||
| Q3 25 | $8.8M | $-60.7M | ||
| Q2 25 | $5.9M | $-71.8M | ||
| Q1 25 | $3.0M | $-84.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $20.3M | $-84.1M | ||
| Q2 24 | $-4.5M | — | ||
| Q1 24 | $-4.8M | $-72.4M |
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 76.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 75.5% | — |
| Q4 25 | 22.7% | -91.3% | ||
| Q3 25 | 17.6% | -125.2% | ||
| Q2 25 | 12.7% | -182.7% | ||
| Q1 25 | 8.7% | -417.9% | ||
| Q4 24 | 22.6% | — | ||
| Q3 24 | 27.4% | -716.6% | ||
| Q2 24 | -4.6% | — | ||
| Q1 24 | -5.3% | — |
| Q4 25 | — | -99.3% | ||
| Q3 25 | 16.2% | -132.4% | ||
| Q2 25 | 11.2% | -189.3% | ||
| Q1 25 | 6.5% | -423.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | -673.0% | ||
| Q2 24 | -9.6% | — | ||
| Q1 24 | -11.0% | — |
| Q4 25 | $0.26 | $-0.78 | ||
| Q3 25 | $0.17 | $-0.70 | ||
| Q2 25 | $0.12 | $-0.83 | ||
| Q1 25 | $0.06 | $-0.98 | ||
| Q4 24 | $0.40 | — | ||
| Q3 24 | $0.41 | $-0.98 | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $-0.10 | $-0.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $97.5M | $394.1M |
| Total DebtLower is stronger | $22.7M | — |
| Stockholders' EquityBook value | $130.3M | $64.6M |
| Total Assets | $216.3M | $529.7M |
| Debt / EquityLower = less leverage | 0.17× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $97.5M | $394.1M | ||
| Q3 25 | $94.4M | $436.0M | ||
| Q2 25 | $96.0M | $455.2M | ||
| Q1 25 | $93.2M | $512.2M | ||
| Q4 24 | $101.0M | — | ||
| Q3 24 | $96.7M | $389.6M | ||
| Q2 24 | $96.8M | — | ||
| Q1 24 | $107.2M | $434.6M |
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — | ||
| Q1 24 | $102.0M | — |
| Q4 25 | $130.3M | $64.6M | ||
| Q3 25 | $115.3M | $115.4M | ||
| Q2 25 | $104.7M | $157.4M | ||
| Q1 25 | $97.1M | $215.1M | ||
| Q4 24 | $92.1M | — | ||
| Q3 24 | $71.1M | $366.4M | ||
| Q2 24 | $48.5M | — | ||
| Q1 24 | $51.0M | $491.9M |
| Q4 25 | $216.3M | $529.7M | ||
| Q3 25 | $202.9M | $551.8M | ||
| Q2 25 | $194.9M | $596.1M | ||
| Q1 25 | $196.2M | $640.7M | ||
| Q4 24 | $213.3M | — | ||
| Q3 24 | $220.7M | $425.8M | ||
| Q2 24 | $205.0M | — | ||
| Q1 24 | $214.1M | $543.0M |
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.4M | $-69.5M |
| Free Cash FlowOCF − Capex | $14.4M | — |
| FCF MarginFCF / Revenue | 19.1% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $41.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | $-69.5M | ||
| Q3 25 | $9.7M | $-70.5M | ||
| Q2 25 | $14.1M | $-87.8M | ||
| Q1 25 | $3.6M | $-95.2M | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $11.0M | $-62.3M | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | $11.2M | $-83.5M |
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | — | ||
| Q2 25 | $14.1M | — | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $11.0M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | — | — |
| Q4 25 | 19.1% | — | ||
| Q3 25 | 17.7% | — | ||
| Q2 25 | 26.8% | — | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | 13.7% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.10× | — | ||
| Q2 25 | 2.41× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
